Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins (Q35164399)

6 August 2017

title

Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins (English)

1 reference

6 August 2017

1 reference

Yawu Jing

1

1 reference

6 August 2017

Huarui Lu

2

1 reference

6 August 2017

Kailang Wu

3

1 reference

6 August 2017

Indira V Subramanian

4

1 reference

6 August 2017

S Ramakrishnan

5

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

6 August 2017

number of pages

11

1 reference

International Journal of Cancer

inferred from page(s)

published in

1 reference

6 August 2017

volume

129

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

751-761

1 reference

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Effects of endostatin production on oncogenicity and metastatic activity of HPV16-transformed mouse cells: role of interleukin 1alpha

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Strategies to extend plasma half-lives of recombinant antibodies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Antiangiogenic drugs in ovarian cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Fc-based cytokines : prospects for engineering superior therapeutics

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Angiogenesis in normal and neoplastic ovaries

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Endogenous angiogenesis inhibitors and their therapeutic implications

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Interaction of endostatin with integrins implicated in angiogenesis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Designing CD4 immunoadhesins for AIDS therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

28 July 2018

1 reference

Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer

21 January 2018

1 reference

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

21 January 2018

1 reference

Interaction of endostatin with integrins implicated in angiogenesis

21 January 2018

1 reference

Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth

21 January 2018

1 reference

Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy

21 January 2018

1 reference

Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice

21 January 2018

1 reference

Pathways mediating VEGF-independent tumor angiogenesis

21 January 2018

1 reference

Targeting the tumour vasculature: insights from physiological angiogenesis

21 January 2018

1 reference

Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells

21 January 2018

1 reference

Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3156090

Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21225621

12 December 2020

inferred from PubMed ID database lookup

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21225621

12 December 2020

inferred from PubMed ID database lookup

High level expression and secretion of Fc-X fusion proteins in mammalian cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21225621

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1002/IJC.25932

1 reference

6 August 2017

1 reference

6 August 2017

1 reference